New hope for lung cancer patients with no PD-L1 marker
NCT ID NCT05690945
First seen Nov 18, 2025 · Last updated May 16, 2026 · Updated 20 times
Summary
This study tests a new drug called QL1706 combined with chemotherapy for people with advanced non-small cell lung cancer that does not have the PD-L1 protein. About 606 adults will be randomly assigned to receive either QL1706 with chemo or another drug (tislelizumab) with chemo. The goal is to see if the new combination helps patients live longer and controls the cancer better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.